Snake venom enzyme could boost stroke recovery in rare brain clot study

NCT ID NCT07352358

Disease control Sponsor: Xuanwu Hospital, Beijing Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding batroxobin, a snake venom enzyme that dissolves clots, to standard blood thinners helps people with acute cerebral venous thrombosis (a rare stroke caused by a clot in a brain vein). Seventy-two adults will be randomly assigned to receive either standard anticoagulation alone or anticoagulation plus batroxobin. The main goal is to see if more patients achieve complete clot clearance within 7 days with the combination therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: batroxobin (a snake venom enzyme that breaks down blood clots) plus standard anticoagulants (low-molecular-weight heparin, warfarin, rivaroxaban, or dabigatran)
What this could lead to: If successful, this combination could speed up clot removal and improve recovery for people with cerebral venous thrombosis, a rare type of stroke.
What could go wrong: This is a small, early-phase 4 trial with only 72 participants, so results may not apply broadly. Batroxobin can increase bleeding risk, especially when combined with blood thinners.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged ≥18 years; 2. Neuroimaging confirmed acute CVT; 3. Symptoms onset was within 30 days prior to enrollment; 4. Signed the informed consent form. Exclusion Criteria: 1. Patients with bleeding (including those with bleeding disorders due to coagulation and vascular disorders, active peptic ulcers, suspected intracranial hemorrhage, thrombocytopenic purpura, hemophilia, during menstruation, during surgery, urinary tract bleeding, hemoptysis, premature delivery, miscarriage, women immediately after delivery and during the puerperium with bleeding from the sexual organs, etc.); 2. Recently operated patients 3. Patients with a potential for bleeding (such as those with visceral tumors, diverticulitis of the digestive tract, colitis, subacute bacterial endocarditis, severe hypertension, and severe diabetes, etc.); 4. Those who are currently taking anticoagulant drugs and platelet function inhibitors (such as aspirin) and those who are using antifibrinolytic agents; 5. Those with a pre-medication fibrinogen concentration lower than 100 mg/dl; 6. Patients with severe liver or kidney dysfunction and other conditions such as papillary muscle rupture, ventricular septal perforation, cardiogenic shock, and multiple organ failure. 7. Those who have a history of allergy to this preparation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral venous thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral sinovenous thrombosis intracranial thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral venous thrombosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Snake venom enzyme could boost stroke recovery in rare brain clot study

What the study statuses mean